Quote:

---

slcimmuno Member Level Thursday, 05/18/17 07:50:25 PM
Re: Waverunner1 post# 182527
Post # of 182567

Exactly - Data presented so far in IBD is excellent, backed by Endoscopy subscores... highly suggestive of its potential. And it's not like the IBD biologics efficacy bar is that high, compounded by side-effects and their treatment take and failure rates.

As to B-OM - a placebo-controlled study that showed the active arm vastly outperformed control in Preventing, not just delayed onset, of severe mucositis. Fast track already maybe Breakthrough will be next.

Brilacidin is for real. The topical application is just beginning to be realized. And given its effectiveness with negligible levels of absorption its expansion into other areas is, well, almost a given.

So put on the shades (so to speak), but don't lose the 20/20 vision, the ability to cut through the fog, as to CTIX: The science continues to advance and impress and will reward the patient... and patients, which matters most of all.

---